Biodesix Stock Performance
BDSX Stock | USD 1.40 0.01 0.71% |
The firm shows a Beta (market volatility) of -0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Biodesix are expected to decrease at a much lower rate. During the bear market, Biodesix is likely to outperform the market. At this point, Biodesix has a negative expected return of -0.25%. Please make sure to confirm Biodesix's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Biodesix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biodesix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Disposition of 434 shares by Gary Pestano of Biodesix at 1.4795 subject to Rule 16b-3 | 09/04/2024 |
2 | Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study | 10/07/2024 |
3 | Disposition of 327 shares by Robin Cowie of Biodesix subject to Rule 16b-3 | 10/11/2024 |
4 | Acquisition by Scott Hutton of 180926 shares of Biodesix at 1.46 subject to Rule 16b-3 | 10/22/2024 |
5 | Acquisition by Vazquez Chris of tradable shares of Biodesix subject to Rule 16b-3 | 10/25/2024 |
6 | What To Expect From Biodesix Inc Q3 2024 Earnings | 10/31/2024 |
7 | Biodesix Announces Third Quarter 2024 Results and Highlights | 11/01/2024 |
8 | Biodesix, Inc. Q3 2024 Earnings Call Transcript | 11/04/2024 |
9 | Acquisition by Kennedy Lawrence T. Jr of 51200 shares of Biodesix at 1.365 subject to Rule 16b-3 | 11/05/2024 |
10 | Biodesix director Matthew Strobeck acquires 55,915 in stock | 11/06/2024 |
11 | Biodesix, Inc. Shares Bought by Perkins Capital Management Inc. | 11/07/2024 |
12 | Disposition of 500 shares by Robin Cowie of Biodesix at 1.3909 subject to Rule 16b-3 | 11/11/2024 |
13 | Disposition of 471 shares by Robin Cowie of Biodesix at 1.4008 subject to Rule 16b-3 | 11/12/2024 |
14 | Biodesix chief commercial officer sells shares worth 644 | 11/13/2024 |
Begin Period Cash Flow | 43.2 M |
Biodesix |
Biodesix Relative Risk vs. Return Landscape
If you would invest 174.00 in Biodesix on August 16, 2024 and sell it today you would lose (34.00) from holding Biodesix or give up 19.54% of portfolio value over 90 days. Biodesix is currently does not generate positive expected returns and assumes 4.1943% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Biodesix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Biodesix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biodesix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biodesix, and traders can use it to determine the average amount a Biodesix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0594
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | BDSX |
Estimated Market Risk
4.19 actual daily | 37 63% of assets are more volatile |
Expected Return
-0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biodesix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biodesix by adding Biodesix to a well-diversified portfolio.
Biodesix Fundamentals Growth
Biodesix Stock prices reflect investors' perceptions of the future prospects and financial health of Biodesix, and Biodesix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biodesix Stock performance.
Return On Equity | -3.32 | ||||
Return On Asset | -0.23 | ||||
Profit Margin | (0.67) % | ||||
Operating Margin | (0.47) % | ||||
Current Valuation | 235.66 M | ||||
Shares Outstanding | 145.47 M | ||||
Price To Book | 7.36 X | ||||
Price To Sales | 3.13 X | ||||
Revenue | 49.09 M | ||||
EBITDA | (35.79 M) | ||||
Cash And Equivalents | 15.18 M | ||||
Cash Per Share | 0.36 X | ||||
Total Debt | 60.69 M | ||||
Debt To Equity | 3.20 % | ||||
Book Value Per Share | 0.19 X | ||||
Cash Flow From Operations | (22.87 M) | ||||
Earnings Per Share | (0.37) X | ||||
Total Asset | 99.1 M | ||||
Retained Earnings | (419.57 M) | ||||
About Biodesix Performance
Evaluating Biodesix's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Biodesix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biodesix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado. Biodesix operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 218 people.Things to note about Biodesix performance evaluation
Checking the ongoing alerts about Biodesix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biodesix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Biodesix generated a negative expected return over the last 90 days | |
Biodesix may become a speculative penny stock | |
Biodesix has high historical volatility and very poor performance | |
Biodesix has a very high chance of going through financial distress in the upcoming years | |
Biodesix currently holds 60.69 M in liabilities with Debt to Equity (D/E) ratio of 3.2, implying the company greatly relies on financing operations through barrowing. Biodesix has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biodesix's use of debt, we should always consider it together with its cash and equity. | |
The entity reported the previous year's revenue of 49.09 M. Net Loss for the year was (52.15 M) with profit before overhead, payroll, taxes, and interest of 24.06 M. | |
Biodesix currently holds about 15.18 M in cash with (22.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36. | |
Roughly 47.0% of Biodesix shares are held by company insiders | |
Latest headline from investing.com: Biodesix chief commercial officer sells shares worth 644 |
- Analyzing Biodesix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biodesix's stock is overvalued or undervalued compared to its peers.
- Examining Biodesix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biodesix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biodesix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biodesix's stock. These opinions can provide insight into Biodesix's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Biodesix Stock Analysis
When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.